Fig. 5

Correlation of △ASM/W with △LFC (A) and △HOMA-IR (B) in all patients. HOMA-IR, homeostatic model assessment of insulin resistance; ALT, alanine aminotransferase, LFC, liver fat content; ASM, appendicular skeletal mass; ASM/W, ASM/weight. Receiver operating characteristic curve of △ASM/W for predicting normalization of HOMA-IR in subjects with insulin resistance at baseline (n=116, C), normalization of ALT in subjects with elevation of ALT at baseline (n=194, D), △LFC reduction ≥30% in the entire cohort (n=256, E). △ASM/W=ASM/W _{Follow-up-Baseline}; △HOMA-IR=HOMA-IR _{Baseline-Follow-up}; △LFC= LFC _{Baseline-Follow-up}. Insulin resistance was defined as a homeostasis model assessment of insulin resistance ≥2.5, and normalization of HOMA-IR was defined as a homeostasis model assessment of insulin resistance<2.5 at follow-up in this cohort. Elevation of ALT was defined as alanine aminotransferase ≥30 U/L in males and ≥19 U/L in females, and the normalization of ALT was determined when alanine aminotransferase <30 U/L in males and <19 U/L in females at follow-up in this cohort. LFC relative reduction was calculated as relative △LFC _{Baseline-Follow-up}/ LFC _Baseline